[PDF][PDF] Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors
The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …
Clinical development of targeted and immune based anti-cancer therapies
NA Seebacher, AE Stacy, GM Porter… - Journal of Experimental & …, 2019 - Springer
Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
Design of protein-binding proteins from the target structure alone
The design of proteins that bind to a specific site on the surface of a target protein using no
information other than the three-dimensional structure of the target remains a challenge …
information other than the three-dimensional structure of the target remains a challenge …
Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR–STAT3 signalling
Activated EGFR signalling drives tumorigenicity in 50% of glioblastoma (GBM). However,
EGFR-targeting therapy has proven ineffective in treating patients with GBM, indicating that …
EGFR-targeting therapy has proven ineffective in treating patients with GBM, indicating that …
The ErbB/HER family of protein-tyrosine kinases and cancer
R Roskoski Jr - Pharmacological research, 2014 - Elsevier
The human epidermal growth factor receptor (EGFR) family consists of four members that
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …
Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer interface
Human epidermal growth factor receptor 2 (HER2) and HER3 form a potent pro-oncogenic
heterocomplex,–upon binding of growth factor neuregulin-1β (NRG1β). The mechanism by …
heterocomplex,–upon binding of growth factor neuregulin-1β (NRG1β). The mechanism by …
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
J Neijssen, RMF Cardoso, KM Chevalier… - Journal of Biological …, 2021 - ASBMB
A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and
mesenchymal–epithelial transition factor (MET) pathways represents a novel approach to …
mesenchymal–epithelial transition factor (MET) pathways represents a novel approach to …
The ERBB network: at last, cancer therapy meets systems biology
Y Yarden, G Pines - Nature Reviews Cancer, 2012 - nature.com
Although it is broadly agreed that the improved treatment of patients with cancer will depend
on a deeper molecular understanding of the underlying pathogenesis, only a few examples …
on a deeper molecular understanding of the underlying pathogenesis, only a few examples …
[HTML][HTML] Cell signaling by receptor tyrosine kinases
MA Lemmon, J Schlessinger - Cell, 2010 - cell.com
Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected
diversity in the mechanisms of their activation by growth factor ligands. Strategies for …
diversity in the mechanisms of their activation by growth factor ligands. Strategies for …
Targeting the EGFR signaling pathway in cancer therapy
P Seshacharyulu, MP Ponnusamy… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful …
recently been made, wherein EGFR and its family members have emerged as useful …